Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept SC plus standard treatment in adults with active idiopathic inflammatory myopathy
2016-002269-77Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abatacept in Autoimmune Myopathies, dermatomyositis (DM), polymyositis (PM) and 1 more (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects who achieve IMACS DOI at Week 24 without rescue. Started Apr 2017; status: terminated.
02
Drugs
abatacept
03
Conditions
Autoimmune Myopathiesdermatomyositis (DM)polymyositis (PM)immune-mediated necrotizing myopathy (IMNM)
Beyond the preview
Go deeper on 2016-002269-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002269-77.